Fiona Marshall
#170,396
Most Influential Person Now
British pharmacologist
Fiona Marshall 's AcademicInfluence.com Rankings
Fiona Marshall medical Degrees
Medical
#3641
World Rank
#4130
Historical Rank
Pharmacology
#474
World Rank
#531
Historical Rank
Download Badge
Medical
Fiona Marshall 's Degrees
- Bachelors Pharmacology University of Manchester
- Masters Pharmacology University of Manchester
- PhD Pharmacology University of Oxford
Why Is Fiona Marshall Influential?
(Suggest an Edit or Addition)According to Wikipedia, Fiona Hamilton Marshall is a British pharmacologist, founder and Senior Vice President of Discovery, Preclinical & Translational Medicine at Merck & Co. She will become the next president of the Novartis Institutes for BioMedical Research. She previously served as Chief Scientific Officer at Heptares Therapeutic, where she was Vice President of the Japanese biopharmaceutical company Sosei. She was elected Fellow of the Academy of Medical Sciences in 2016 and the Royal Society in 2021.
Fiona Marshall 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids* (2003) (1814)
- Heterodimerization is required for the formation of a functional GABAB receptor (1998) (1197)
- International Union of Pharmacology. XXXIII. Mammalian γ-Aminobutyric AcidB Receptors: Structure and Function (2002) (539)
- Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid* (2003) (503)
- Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. (2011) (494)
- Structure of class B GPCR corticotropin-releasing factor receptor 1 (2013) (390)
- Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain (2014) (373)
- GABAB receptors - the first 7TM heterodimers. (1999) (369)
- Generic GPCR residue numbers - aligning topology maps while minding the gaps. (2015) (330)
- Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design (2012) (296)
- THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview (2017) (266)
- International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. (2002) (254)
- CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain (2002) (226)
- Progress in Structure Based Drug Design for G Protein-Coupled Receptors (2011) (208)
- Insights into the structure of class B GPCRs. (2014) (199)
- The GABAB receptor interacts directly with the related transcription factors CREB2 and ATFx. (2000) (186)
- Extra-helical binding site of a glucagon receptor antagonist (2016) (185)
- RAMPs: accessory proteins for seven transmembrane domain receptors. (1999) (172)
- Intracellular allosteric antagonism of the CCR9 receptor (2016) (168)
- New insights from structural biology into the druggability of G protein-coupled receptors. (2012) (163)
- Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. (2017) (161)
- Structural insight into allosteric modulation of protease-activated receptor 2 (2017) (158)
- Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design (2013) (151)
- Crystal structure of the GLP-1 receptor bound to a peptide agonist (2017) (144)
- The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery (2011) (141)
- Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength. (2016) (140)
- Therapeutic antibodies directed at G protein-coupled receptors (2010) (140)
- Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). (2015) (137)
- The impact of GPCR structures on pharmacology and structure‐based drug design (2010) (136)
- Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening (2012) (133)
- Probiotics and immune response. (2000) (126)
- Biophysical Mapping of the Adenosine A2A Receptor (2011) (115)
- Protein-Protein Interaction and Not Glycosylation Determines the Binding Selectivity of Heterodimers between the Calcitonin Receptor-like Receptor and the Receptor Activity-modifying Proteins* (2001) (113)
- Structures of G protein-coupled receptors reveal new opportunities for drug discovery. (2015) (113)
- Advances in the molecular understanding of GABAB receptors (2001) (101)
- Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. (2011) (97)
- Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain (2007) (91)
- Calcium sensing properties of the GABAB receptor (1999) (90)
- Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727 (2018) (90)
- Structure of Class B GPCRs: new horizons for drug discovery (2014) (88)
- Opportunities for therapeutic antibodies directed at G-protein-coupled receptors (2017) (87)
- Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. (2017) (83)
- Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. (2012) (77)
- GABA(B) receptor heterodimer-component localisation in human brain. (2000) (77)
- From G Protein-coupled Receptor Structure Resolution to Rational Drug Design* (2015) (75)
- Cellular and sub-cellular localisation of GABA(B1) and GABA(B2) receptor proteins in the rat cerebellum. (2000) (72)
- Structure-based drug design for G protein-coupled receptors. (2014) (71)
- High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks (2013) (70)
- Pharmacology and physiology of gastrointestinal enteroendocrine cells (2015) (67)
- Opportunities for therapeutic antibodies directed at G-protein-coupled receptors (2017) (65)
- Calcium and phosphorus homeostasis in the parathyroidectomized dog; evaluation by means of ethylenediamine tetraacetate and calcium tolerance tests. (1960) (64)
- Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. (2017) (62)
- Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy (2013) (62)
- Binding kinetics differentiates functional antagonism of orexin‐2 receptor ligands (2014) (61)
- Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals (2018) (61)
- Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray Structures. (2018) (60)
- Biacore analysis with stabilized G-protein-coupled receptors. (2011) (59)
- Development of Tolerance in Mice to the Sedative Effects of the Neuroactive Steroid Minaxolone Following Chronic Exposure (1997) (53)
- Heterodimerization of G-protein-coupled receptors in the CNS. (2001) (53)
- GABA(B) receptors function as heterodimers. (1999) (53)
- The use of GPCR structures in drug design. (2011) (48)
- Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants (2015) (44)
- Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis (2019) (40)
- Is the GABAB heterodimer a good drug target? (2007) (40)
- Atomoxetine produces changes in cortico-basal thalamic loop circuits: Assessed by phMRI BOLD contrast (2007) (38)
- Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast (2006) (38)
- GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 (2015) (35)
- GABAB receptor subunits, R1 and R2, in brainstem catecholamine and serotonin neurons (2003) (33)
- Digestive physiology of the pig symposium: gut chemosensing and the regulation of nutrient absorption and energy supply. (2013) (31)
- Heterodimerization of the GABAB receptor-implications for GPCR signaling and drug discovery. (2010) (30)
- Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals (2018) (30)
- Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment (2014) (28)
- Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. (2015) (28)
- The role of GABA(B) receptors in the regulation of excitatory neurotransmission. (2008) (24)
- Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures (2017) (18)
- Nociception activates Elk‐1 and Sap 1a following expression of the ORL 1 receptor in Chinese hamster ovary cells (1998) (18)
- Differential effects of the d- and l- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat (2007) (18)
- NOBEL 2012 Chemistry: Studies of a ubiquitous receptor family (2012) (17)
- From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease (2021) (17)
- Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast (2009) (16)
- Conformational thermostabilisation of corticotropin releasing factor receptor 1 (2015) (16)
- Characterization of cholecystokinin octapeptide‐stimulated endogenous dopamine release from rat nucleus accumbens in vitro (1990) (16)
- Purification of Stabilized GPCRs for Structural and Biophysical Analyses. (2015) (14)
- Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties (2015) (14)
- Binding of angiotensin antagonists to rat liver and brain membranes measured ex vivo (1993) (13)
- Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression (2017) (13)
- Preparation of purified GPCRs for structural studies. (2013) (12)
- Heterodimerization of γ-aminobutyric acid B receptor subunits as revealed by the yeast two-hybrid system (2002) (11)
- Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation (2022) (11)
- Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion. (1995) (8)
- Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics (2015) (8)
- Visualizing GPCR 'Megaplexes' Which Enable Sustained Intracellular Signaling. (2016) (8)
- Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study (2021) (8)
- First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias (2020) (7)
- Biacore analysis with stabilized GPCRs (2011) (7)
- Abstract 3751: Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models (2018) (7)
- Mammalian-Aminobutyric AcidB Receptors : Structure and Function (2002) (6)
- Heterodimerization of gamma-aminobutyric acid B receptor subunits as revealed by the yeast two-hybrid system. (2002) (5)
- [THE EFFECT OF THE ADRENOCORTICOTROPIC HORMONE ON THE SYMPTOMATOLOGY OF MULTIPLE SCLEROSIS]. (1963) (5)
- Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonist (2017) (4)
- CB1 and CB2 cannabinoid receptors are implicated in inflammatory hypersensitivity to pain (2001) (4)
- Correlation between ulcerogenic and neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its reduced derivative in rats (1987) (4)
- TEMPORARY REMOVAL: Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure- based drug design. (2019) (3)
- Two NK1 agonist responses in the rat superior cervical ganglion (1993) (3)
- New Techniques to Express and Crystallize G Protein‐Coupled Receptors (2010) (2)
- Molecular insight develops our understanding of the GABA(B) receptor. (2000) (2)
- THEMED SECTION: MOLECULAR PHARMACOLOGY OF G PROTEIN-COUPLED RECEPTORS REVIEW The impact of GPCR structures on pharmacology and structure-based drug design (2010) (2)
- Cellular and subcellular localisation of GABA and GABAB 1 B 2 receptor proteins in the rat cerebellum (2000) (1)
- Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 -acetylcholine receptor agonist: A randomized cross-over trial (2021) (1)
- RECENT RESEARCH ON THE SEX HORMONES AND THEIR CYCLICAL PRODUCTION * (1932) (1)
- Advances and Insights from CNS G Protein-Coupled Receptor Crystallography (2017) (1)
- Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution (2017) (1)
- Co-expression of the adenosine A2A receptor and the stimulatory G-protein alpha subunit in a stable cell line using a novel poly-cistronic expression vector (1995) (1)
- High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks (2013) (1)
- Thermostabilised turkey beta1 adrenergic receptor with 4-methyl-2-(piperazin-1-yl) quinoline bound (2013) (0)
- Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in ternary complex with Fab3949 and AZ7188 at 4.0 angstrom resolution (2017) (0)
- Thermostabilised Adenosine A2A receptor in complex with 6-(2,6-Dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine (2012) (0)
- Crystal structure of human corticotropin-releasing factor receptor 1 (CRF1R) in complex with the antagonist CP-376395 (2013) (0)
- Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator 3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile - (HTL14242) (2015) (0)
- Crystal structure of the Orexin-1 receptor in complex with SB-334867 (2020) (0)
- Crystal Structure of mGluR5 in complex with MMPEP at 2.2 A (2018) (0)
- Thermostabilised adenosine A2A receptor in complex with XAC (2011) (0)
- Crystal structure of human corticotropin-releasing factor receptor 1 (CRF1R) in complex with the antagonist CP-376395 in a hexagonal setting with translational non-crystallographic symmetry (2016) (0)
- Crystal structure of the Orexin-1 receptor in complex with lemborexant (2020) (0)
- Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator mavoglurant (2014) (0)
- Structure of the A2A-StaR2-bRIL562-Tozadenant complex at 3.1A obtained from in meso soaking experiments. (2018) (0)
- Crystal structure of the Orexin-1 receptor in complex with filorexant (2020) (0)
- Crystal structure of the Orexin-1 receptor in complex with daridorexant (2020) (0)
- Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial (2021) (0)
- Crystal structure of the human CC chemokine receptor type 9 (CCR9) in complex with vercirnon (2016) (0)
- Heterodimerisation of GABAB receptors (1999) (0)
- Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12b at 2.2A resolution (2016) (0)
- Structure of the A2A-StaR2-bRIL562-ZM241385 complex at 1.86A obtained from in meso soaking experiments. (2018) (0)
- GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014 (2015) (0)
- Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study (2021) (0)
- Crystal structure of the Orexin-2 receptor in complex with HTL6641 at 2.61 A resolution (2020) (0)
- Crystal structure of the Orexin-1 receptor in complex with SB-408124 (2020) (0)
- Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator 3-chloro-4-fluoro-5-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzonitrile (2015) (0)
- Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ8838 at 2.8 angstrom resolution (2017) (0)
- Crystal structure of the Orexin-1 receptor in complex with ACT-462206 (2020) (0)
- A summary and conclusions from the meeting (2007) (0)
- Abstract 2641: AZD4635 A2Areceptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program (2017) (0)
- Crystal structure of thermostabilised human C5a anaphylatoxin chemotactic receptor 1 (C5aR) in complex with NDT9513727 (2018) (0)
- Crystal structure of the Orexin-1 receptor in complex with EMPA (2020) (0)
- Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ3451 at 3.6 angstrom resolution (2017) (0)
- On Variation in the Number and Arrangement of the Male Genital Apertures in the Norway Lobster (Nephrops norvegicus) (2010) (0)
- Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.86A obtained from in meso soaking experiments (24 hour soak). (2018) (0)
- CHAPTER 9:Molecular Biology for Medicinal Chemists (2014) (0)
- Crystal structure of the Orexin-2 receptor in complex with EMPA at 2.74 A resolution (2020) (0)
- GABAB receptors are multimeric protein complexes (1999) (0)
- Thermostabilised adenosine A2A receptor in complex with caffeine (2011) (0)
- Crystal structure of the Orexin-2 receptor in complex with suvorexant at 2.76 A resolution (2020) (0)
- Crystal structure of the Orexin-1 receptor in complex with GSK1059865 (2020) (0)
- Thermostabilised turkey beta1 adrenergic receptor with 4-(piperazin-1- yl)-1H-indole bound (compound 19) (2013) (0)
- StaR engineering: GPCR stabilisation for structure‐based drug design (2013) (0)
- Crystal structure of the Orexin-1 receptor in complex with Compound 16 (2020) (0)
- Crystal structure of thermostabilised full-length GLP-1R in complex with a truncated peptide agonist at 3.7 A resolution (2017) (0)
- Crystal Structure of mGluR5 in complex with Fenobam at 2.65 A (2018) (0)
- Crystal structure of the Orexin-1 receptor in complex with suvorexant at 2.29 A resolution (2020) (0)
- Structural elucidation of ligand binding sites in family B GPCRs and their application in drug discovery (2016) (0)
- Thermostabilised Adenosine A2A receptor in complex with 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol (2012) (0)
- Crystal structure of the human glucagon receptor (GCGR) in complex with the antagonist MK-0893 (2016) (0)
- From Structure to Clinic: Discovery of A M1 Muscarinic Acetylcholine Receptor Agonist for the Treatment of Memory Loss in Alzheimer's Disease (2020) (0)
- The effects of one-sided ovariotomy on the sex of the offspring (1910) (0)
- Crystal Structure of the A2A-StaR2-bRIL562 in complex with AZD4635 at 2.0A resolution (2019) (0)
- Crystal structure of the Orexin-1 receptor in complex with Compound 14 (2020) (0)
- Thermostabilised Adenosine A2A Receptor (2011) (0)
- S.01.02 Novel strategies for probing 3D structures of GPCRs (2013) (0)
- Increased charges for lenses (1985) (0)
- P.1.002 Pharmacological characterisation of positive allosteric modulators acting on the metabotropic glutamate receptor 2 (2013) (0)
- PMWS-Related but Diet-Induced Colitis (2007) (0)
- Review for "Pharmacological validation of TDO as a target for Parkinson’s disease" (2020) (0)
- The novel M4 PAM PET tracer [11C] MK‐6884: a novel biomarker for measuring target engagement of muscarinic M4 positive allosteric modulators (PAMs) as well as cholinergic tone in patients with Alzheimer’s disease (2022) (0)
This paper list is powered by the following services:
Other Resources About Fiona Marshall
What Schools Are Affiliated With Fiona Marshall ?
Fiona Marshall is affiliated with the following schools:
